Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | TYMS | P04818 | 1/20 | 0.52 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.52 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.52 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.44 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1100896 | 0.98 | LPAR3 (0.56) | ALDH1A1TDP1TYMSLPAR3LPAR2 | |
| SCHEMBL1100844 | 0.98 | LPAR3 (0.56) | ALDH1A1TDP1TYMSLPAR3LPAR2 | |
| SCHEMBL15510572 | 0.98 | LPAR3 (0.56) | ALDH1A1TDP1TYMSLPAR3LPAR2 | |
| SCHEMBL1100535 | 0.98 | LPAR3 (0.56) | ALDH1A1TDP1TYMSLPAR3LPAR2 | |
| SCHEMBL1100245 | 0.98 | LPAR3 (0.56) | ALDH1A1TDP1TYMSLPAR3LPAR2 | |
| SCHEMBL1101281 | 0.98 | LPAR3 (0.56) | ALDH1A1TDP1TYMSLPAR3LPAR2 | |
| SCHEMBL1099485 | 0.98 | LPAR3 (0.56) | ALDH1A1TDP1TYMSLPAR3LPAR2 | |
| SCHEMBL1100677 | 0.98 | LPAR3 (0.56) | ALDH1A1TDP1TYMSLPAR3LPAR2 | |
| SCHEMBL1100638 | 0.98 | LPAR3 (0.56) | ALDH1A1TDP1TYMSLPAR3LPAR2 | |
| SCHEMBL700557 | 0.92 | ALDH1A1 (0.67) | ALDH1A1TDP1TYMSLPAR3LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240170294-A1 | Silicon Etching Solution, Method for Treating Substrate, and Method for Manufacturing Silicon Device | TOKUYAMA CORPORATION (JP) | 2024-05-23 | — | — | US | claimed |
| WO-2024204794-A1 | ETCHING LIQUID FOR SILICON NITRIDES, METHOD FOR PROCESSING SUBSTRATE AND METHOD FOR PRODUCING SEMICONDUCTOR ELEMENT | 株式会社トクヤマ | 2024-10-03 | — | — | WO | disclosed |
| US-20240170294-A1 | Silicon Etching Solution, Method for Treating Substrate, and Method for Manufacturing Silicon Device | TOKUYAMA CORPORATION (JP) | 2024-05-23 | — | — | US | disclosed |
| US-20230295457-A1 | SURFACE TREATMENT LIQUID AND SURFACE TREATMENT METHOD | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20180002312-A1 | TETRA- AND PENTASUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS USEFUL IN THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002312-A1 | TETRA- AND PENTASUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS USEFUL IN THE TREATMENT OF RESPIRATORY DISEASES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, F12, HRH4 | ALDH1A1 1331/4885TDP1 2814/4885TYMS 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.